Regional brain activation during rectal distention and attenuation with alosetron in a nonhuman primate model of irritable bowel syndrome.
Macaca fascicularis
cingulate cortex
insular/secondary somatosensory cortex; neuroimaging; translational
manometry
visceral hypersensitivity
Journal
FASEB bioAdvances
ISSN: 2573-9832
Titre abrégé: FASEB Bioadv
Pays: United States
ID NLM: 101733210
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
02
05
2022
revised:
16
08
2022
accepted:
17
08
2022
entrez:
9
11
2022
pubmed:
10
11
2022
medline:
10
11
2022
Statut:
epublish
Résumé
Greater understanding of the mechanism that mediates visceral pain and hypersensitivity associated with irritable bowel syndrome (IBS) would facilitate the development of effective therapeutics to manage these symptoms. An objective marker associated with the underlying mechanisms of visceral pain and hypersensitivity could be used to guide therapeutic development. The current study examined brain activation evoked by rectal distention with functional magnetic resonance imaging (fMRI) in a cynomolgus macaque model of visceral hypersensitivity. Male, cynomolgus macaques underwent five four-week treatments of dextran sodium sulfate (DSS)-distilled water (DW), which induced mild-moderate colitis with remission during each treatment cycle. Balloon rectal distention (RD) was performed under anesthesia 14 weeks after the final DSS-DW treatment. Colonoscopy confirmed the absence of colitis prior to the start of RD. In naïve, untreated macaques, 10, 20 and 30 ml RD did not evoke brain activation. However, insular cortex/somatosensory II cortex and cerebellum were significantly activated in DSS-treated macaques at 20 and 30 ml rectal distention. Intra-rectal pressure after DSS treatment was not significantly different from that of naïve, untreated macaques, indicating lack of alteration of rectal functioning following DSS-treatment. Treatment with 5-HT
Identifiants
pubmed: 36349296
doi: 10.1096/fba.2022-00048
pii: FBA21345
pmc: PMC9635009
doi:
Types de publication
Journal Article
Langues
eng
Pagination
694-708Informations de copyright
© 2022 The Authors. FASEB BioAdvances published by Wiley Periodicals LLC on behalf of The Federation of American Societies for Experimental Biology.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Aliment Pharmacol Ther. 2010 May;31(9):979-90
pubmed: 20163375
Br J Pharmacol. 2004 Apr;141(8):1303-12
pubmed: 15023866
Inflamm Bowel Dis. 2016 Jun;22(6):1296-305
pubmed: 27104821
Pain. 2018 Jul;159(7):1325-1345
pubmed: 29561359
J Immunol. 2004 Mar 1;172(5):2731-8
pubmed: 14978070
Aliment Pharmacol Ther. 2002 Jul;16(7):1357-66
pubmed: 12144587
Nat Rev Dis Primers. 2016 Mar 24;2:16014
pubmed: 27159638
In Vivo. 2002 May-Jun;16(3):191-5
pubmed: 12182115
Front Microbiol. 2018 Nov 30;9:2897
pubmed: 30555441
Heliyon. 2020 Jan 09;6(1):e03178
pubmed: 31938753
Anesth Prog. 2001 Spring;48(2):66-71
pubmed: 11515950
J Cereb Blood Flow Metab. 2016 May;36(5):842-61
pubmed: 26945019
CNS Neurol Disord Drug Targets. 2018;17(5):348-360
pubmed: 29766827
Front Immunol. 2018 Dec 04;9:2862
pubmed: 30568659
Neurogastroenterol Motil. 2020 Apr;32(4):e13776
pubmed: 31833625
Curr Opin Pharmacol. 2007 Dec;7(6):598-604
pubmed: 18006379
Pain. 1990 Dec;43(3):377-386
pubmed: 2293146
Aliment Pharmacol Ther. 2008 Aug 1;28(3):344-52
pubmed: 19086332
Cerebellum. 2017 Apr;16(2):508-517
pubmed: 27797090
Neuroimage. 2018 May 15;172:642-653
pubmed: 29421324
Gut. 1996 Jul;39(1):109-13
pubmed: 8881820
Mucosal Immunol. 2019 Nov;12(6):1327-1335
pubmed: 31481749
Aliment Pharmacol Ther. 1999 May;13 Suppl 2:70-6
pubmed: 10429744
J Neurogastroenterol Motil. 2016 Oct 30;22(4):558-574
pubmed: 27431236
Am J Physiol Gastrointest Liver Physiol. 2013 Dec;305(11):G763-85
pubmed: 23989010
Neuropharmacology. 2019 May 1;149:204-211
pubmed: 30817933
Gut. 1973 Feb;14(2):125-32
pubmed: 4696535
Gastroenterology. 1997 Jan;112(1):64-72
pubmed: 8978344
Drugs R D. 2008;9(1):37-63
pubmed: 18095752
Gut. 2019 Sep;68(9):1701-1715
pubmed: 31175206
Br J Anaesth. 2018 Jul;121(1):281-290
pubmed: 29935583
Nat Commun. 2015 Aug 18;6:8020
pubmed: 26282376
Gut. 2005 May;54(5):601-7
pubmed: 15831901
Expert Rev Gastroenterol Hepatol. 2011 Feb;5(1):43-57
pubmed: 21309671
PLoS One. 2016 Jul 22;11(7):e0157347
pubmed: 27448273
Neurogastroenterol Motil. 2015 Oct;27(10):1354-70
pubmed: 26088804
World J Gastroenterol. 2003 Jun;9(6):1356-60
pubmed: 12800256
J Neurogastroenterol Motil. 2015 Jul 30;21(3):361-9
pubmed: 26130632
Neuroimage. 2007;37 Suppl 1:S80-8
pubmed: 17512757
Neuron. 2019 Nov 20;104(4):637-653
pubmed: 31751545
Aliment Pharmacol Ther. 2021 Dec;54 Suppl 1:S75-S88
pubmed: 34927753
Br J Anaesth. 2018 Jul;121(1):291-302
pubmed: 29935584
Nucl Med Biol. 1997 Jul;24(5):405-12
pubmed: 9290075
Gut Pathog. 2015 Nov 10;7:29
pubmed: 26561503
Br J Anaesth. 2018 Feb;120(2):299-307
pubmed: 29406179
J Pharmacol Exp Ther. 2009 Jun;329(3):1048-55
pubmed: 19325032
BMJ. 1989 Jan 14;298(6666):82-6
pubmed: 2563951
Gastroenterology. 2000 May;118(5):842-8
pubmed: 10784583
N Engl J Med. 1987 Dec 24;317(26):1625-9
pubmed: 3317057
Mol Pain. 2016 Jun 17;12:
pubmed: 27317579
Nat Rev Gastroenterol Hepatol. 2010 Jan;7(1):15-29
pubmed: 19949430
Gut. 2008 Mar;57(3):384-404
pubmed: 17965064
Am J Gastroenterol. 2008 Oct;103(10):2562-9
pubmed: 18775020
BMC Gastroenterol. 2017 Dec 08;17(1):148
pubmed: 29216847
J Neurophysiol. 2003 Jun;89(6):3294-303
pubmed: 12611986
Pain. 2017 Apr;158 Suppl 1:S115-S122
pubmed: 28141634
J Psychosom Res. 2008 Jun;64(6):599-604
pubmed: 18501260
Arzneimittelforschung. 2012 Apr;62(4):157-66
pubmed: 22438071
J Am Assoc Lab Anim Sci. 2020 Jan 1;59(1):94-103
pubmed: 31753062